Immorta Bio's SenoVax™ Shows Tumor Reduction Across Multiple Cancer Types in Preclinical Study
核心洞察
Immorta Bio (搜索) published preclinical data in the Journal of Translational Medicine showing SenoVax™ significantly reduced tumors in mouse models of lung, brain, pancreatic, and breast cancers.
The novel immunotherapy targets senescent cells to reprogram the tumor microenvironment, converting immunologically "cold" tumors to "hot" by boosting CD8+ T-cell infiltration.
The company has filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer and is completing GMP manufacturing requirements.
Immorta Bio (搜索) announced the publication of preclinical data demonstrating that its novel immunotherapy SenoVax™ achieved significant tumor reduction across multiple cancer types in validated mouse models. The study, published in the Journal of Translational Medicine and titled "Reduction of Solid Tumors by Senescent Cell Immunization," represents a collaboration with leading researchers from the University of Miami, Cedars-Sinai, UC San Diego (搜索), the Institute for Human Optimization, George Washington University, and Translational and Advanced Biosciences.
Novel Mechanism Targets Senescent Cells
SenoVax™ is a personalized autologous immunotherapy that trains the immune system to attack senescent cells, which accumulate with age and chronic stress. These cells are increasingly implicated in creating an immunosuppressive, pro-tumor microenvironment. By targeting antigens uniquely expressed on senescent cells, SenoVax™ appears to reprogram the tumor microenvironment, converting immunologically "cold" tumors to "hot" by boosting CD8+ T-cell infiltration and reducing immune-suppressive cell populations.
The therapy achieved significant tumor shrinkage across lung, glioblastoma (brain), pancreatic, and breast cancers in well-characterized mouse models of aggressive cancers.
Key Preclinical Findings
The study demonstrated several critical outcomes:
- Statistically significant tumor growth inhibition and prolonged survival in both orthotopic and syngeneic models
- Robust CD8+ T-cell infiltration and depletion of immunosuppressive cells in treated tumors
- Strong activity as monotherapy and in combination with other treatments
"These data provide compelling proof-of-concept that immunizing against senescent cells represents an entirely new therapeutic modality in oncology," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio (搜索) and lead author of the study.
Clinical Development Progress
Immorta Bio (搜索) has already filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer and is completing the GMP manufacturing required to begin the study. The regulatory filing positions the company to advance this novel approach into human testing.
Dr. Gilberto Lopes, Chief of Thoracic Medical Oncology at the Sylvester Comprehensive Cancer Center (University of Miami) and study co-author, highlighted the potential clinical impact: "Many deadly solid tumors remain resistant to current immunotherapies because they are immunologically 'cold.' Converting the tumor microenvironment into a more inflamed, T-cell-friendly state by eliminating senescent cells could dramatically broaden the reach of checkpoint inhibitors and other immune therapies."
Broader Therapeutic Implications
Dr. Boris Reznik, Chairman and CEO of Immorta Bio (搜索) and senior author, noted the broader potential applications: "This publication lays a strong translational foundation for bringing senescent-cell-targeted therapies into the clinic, not only for cancer, but potentially for the many age-related diseases driven by pathologic cellular senescence."
The work builds on prior evidence that removing senescent cells can modify the tumor microenvironment and may enhance antitumor immunity, addressing therapeutic resistance that remains a major challenge, particularly in tumors with limited immune infiltration.